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Abstract 
Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in 
the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the 
world recommending NOACs over vitamin K antagonist oral anticoagulants for initial 
treatment of AF for stroke prevention. Here we describe the evidence collated and the process 
followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential 
Medicines (EML). 
Individual NOACs have been reported to be non-inferior or superior to warfarin in 
preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of 
stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular 
AF compared with warfarin in both RCTs and real-world data. 
The successful inclusion of NOACs in the WHO EML is an important step forward in 
the global fight against cardiovascular morbidity and mortality, especially in low- and middle-
income countries, where the burden of disease is high and limited access to diagnosis and 
treatment translates into a higher burden of morbidity, mortality, and economic costs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in 
the treatment of non-valvular atrial fibrillation (AF) for stroke prevention since, as opposed 
to vitamin K antagonist oral anticoagulants (VKAs), they do not require routine International 
Normalized Ratio (INR) testing and have far fewer drug-drug and drug-food interactions [1]. 
NOACs have shown a favourable balance between efficacy and safety compared with VKAs 
in treating eligible AF patients, with significant reductions in stroke, intracranial 
haemorrhage, and mortality [2]. As a result, major clinical practice guidelines around the 
world recommend NOACs over warfarin for initial treatment of AF for stroke prevention 
[1,3,4]. As costs have substantially declined since the introduction of NOACs in 2009, these 
drugs represent an effective, cost-effective alternative to VKAs for patients with AF, 
especially for those with limited access to health care for whom routine INR monitoring is 
difficult. A 2018 modelling analysis forecasted future trends of ischaemic stroke and death 
rates in AF patients by, comparing the scenario of unchanged oral anticoagulant use in East 
Asia (45% of patients on VKAs; 55% on NOACs) with the alternative scenario of a 
continued increase in NOAC use. NOACs uptake to 90% would help prevent an estimated 
206,315 ischaemic strokes and 139,353 deaths from 2031 to 2050 in East Asia compared 
with unchanged use of oral anticoagulants in this region over the same period [5]. Similarly 
in Europe, the introduction of NOACs in 2010 has been estimated to have led to >88,000 
fewer strokes, thromboembolisms and deaths each year. As an example, a model assuming 
that the rate of edoxaban use were to increase from 11% in 2013 to 75% in 2030 with the 
remaining NOAC-eligible population taking warfarin, an additional 12,000 cases of stroke, 
thromboembolism and death would be avoided annually [5,6]. Information regarding 
increased OAC use or NOAC uptake in low- and middle-income countries or low resource 
settings is scarce, but currently VKA therapy has limitations due to cultural and geographical 
barriers. As an example, among anticoagulated patients, those living in low income countries 
have the worst time in therapeutic range [7]. Therefore, NOACs have been increasingly used 
in these situations. For instance, the proportion of NOACs usage in AF patients has been 
drastically increasing in China in recent years. In a large registry study analysing 189,006 
prescriptions of anticoagulants for AF patients at 67 hospitals in 5 major cities in China, the 
percentage of patients receiving NOACs increased from below 2% in 2012 to 28% in 2017 
[8]. 
In this paper we describe the evidence collated and the process followed for 
developing an application for the inclusion of NOACs into the 21st WHO Model List of 
Essential Medicines (EML); further information is available in the full application [7]. 
Essential medicines are defined as those medicines “that satisfy the priority healthcare needs 
of the population. Essential medicines are intended to be available within the context of 
functioning health systems at all times, in adequate amounts, in appropriate dosage forms, 
with assured quality and adequate information, and at a price the individual and the 
community can afford” [9]. The WHO EML is used as a guide for the development of 
national essential medicine lists and represents a critically important tool for the 
development of national health system policies and practices. Every two years since 1977 the 
WHO Expert Committee on Selection and Use of Essential Medicines reviews submission to 
add, delete, or revise the EML and Model List of Essential Medicines for Children (EMLc) 
based on the most up-to-date scientific evidence on the efficacy, safety and cost-
effectiveness of medicines.  
Application for inclusion of NOACs into the WHO Model List of Essential 
Medicines 
 
A first attempt to include NOACs into the WHO EMLwas undertaken in 2014 [10]. 
Despite the available evidence from randomized controlled trials (RCTs) in terms of efficacy 
and safety of NOACs versus warfarin, the application was rejected because the Committee 
expressed concern that the application’s supporting data came almost exclusively from RCTs, 
highlighting concerns that trial populations may not be representative of patients who would 
receive such treatment in real-world practice [11]. Since 2014, there has been a substantial 
increase in real-world data published with large-scale registry studies, databases of insurance 
claims, and systematic reviews and meta-analysis of NOACs in special-risk populations (e.g. 
elderly, renal impairment, and high HAS-BLED score). Additional safety concerns related to 
the lack of antidotes have also been addressed since the introduction of NOAC-specific 
antidotes. Increasing data on costs and cost-effectiveness also helped overcome some of the 
reasons for the rejection of the 2014 application. 
 
The successful application for the inclusion of NOACs (Dabigatran as representative 
of the pharmacological class) into the 21st WHO EML was led by the World Heart 
Federation Emerging Leaders GOALPoST (improving Global access to Oral AnticoaguLants 
to Prevent Stroke in aTrial fibrillation) team, comprised of academics from different fields 
and different regions in the world who have a goal to increase global access to NOACs 
among eligible AF patients, especially in resource-limited regions. Together, this team 
collated relevant evidence regarding NOACs versus VKAs in AF from pivotal RCTs, large-
scale real-world registries, and cost-effectiveness studies, which supported a robust 
application for the inclusion of NOACs in EML, which was approved by WHO in 2019 
[7,12]. Moreover, to achieve the goal, the study team members are conducting field work in 
Nigeria and Nepal to better understand perceptions and experiences of NOAC usage among 
AF patients and other stakeholders. The Rapid Assessment Protocol for Insulin Access [13] 
to explore the path of the drugs from their production to their final use amongst patients, with 
the aim to identify bottlenecks that may hinder the access to NOACs among patients.  Results 
of this study will inform key actors of the nature of those barriers, leading to an increase in 
the use of oral anticoagulants for NVAF and specifically NOACs, and along with this, many 
strokes, bleedings, and deaths might be avoided, especially in resource limited settings. 
 
Efficacy and safety of NOACs versus VKAs: evidence from RCTs and real-world data  
A brief summary of the characteristics of the 4 NOACs are provided in Table 1. The 
efficacy and safety of NOACs (Dabigatran, Apixaban, Rivaroxaban, Edoxaban) versus VKAs 
(mostly warfarin in RCTs and in clinical practice) in preventing stroke and systemic 
embolism in non-valvular AF patients have been investigated in individual pivotal RCTs 
including Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) [14], 
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-
AF) [15], ROCKET AF in Japanese patients (J-ROCKET AF) [16], Apixaban for Reduction 
in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) [17], and 
Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–
Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) [18] trials, in numerous 
systematic reviews and meta-analysis, as well as in real-word data studies. We updated 
currently available evidence regarding the efficacy and safety of NOACs, individually or as a 
group, compared with warfarin in treating non-valvular AF patients, in the application to 
include NOACs in the WHO EML [7]. The efficacy outcomes of individual and all NOACs 
versus warfarin from RCTs and safety outcomes from real-world studies are shown in 
Figures 1 and 2, respectively. 
 
Individual NOACs have been reported to be non-inferior or superior to warfarin in 
preventing stroke and systemic embolism in eligible AF patients. In a meta-analysis of the 5 
RCTs (59,819 patients), NOACs reduced the risk of stroke and systemic embolism by 20% in 
patients with non-valvular AF compared with warfarin (RR 0.80, 95% CI 0.71-0.91; 
p=0.0003; Figure 1). A similar result in terms of direction and magnitude was observed in 
meta-analysis of real-world data from 12 studies with 520,859 patients (RR 0.79, 95% CI 
0.71-0.89; p<0.001). No real-world data were available from large-scale studies for the 
associations between edoxaban versus warfarin and risk of stroke and systemic embolism [7].  
 
The safety of NOACs has been evaluated by the risk of major bleeding. In meta-
analysis of the 5 major RCTs (59,776 patients), NOACs were associated with a lower risk of 
major bleeding compared with warfarin in patients with non-valvular AF (RR 0.86, 95% CI 
0.74-0.99; p=0.04; Figure 2). Further, a meta-analysis of 17 studies with real-world data 
(622,720 patients) demonstrate a similar direction and possible larger magnitude of effect on 
major bleeding among non-valvular AF patients treated with NOACs compared with warfarin 
(RR 0.72, 95% CI 0.64-0.80; p<0.001; Figure 2), though these results may be partially 
driven by residual confounding in these non-randomized comparisons.  
 
Unlike RCTs, there is greater risk of bias and between-study heterogeneity in the 
design and patient characteristics of real-world studies [7]. However, patients involved in 
observational studies often represent a broader, more diverse, and more complex patient 
population treated with NOACs compared with highly selected patients in RCTs. Indeed, 
synthesized findings from these studies have further corroborated conclusions about the 
safety and efficacy of NOACs versus warfarin in preventing stroke and systemic embolism in 
patients with non-valvular AF derived from RCTs.  
 
Evidence for the use of NOACs in elderly patients 
A persistent concern about NOACs has been their safety in elderly AF patients, but 
recent data have been reassuring. First, data from the Prevention of thromboembolic events-
European Registry in Atrial Fibrillation (PREFER-AF) registry showed net clinical benefit of 
anticoagulation versus no anticoagulation, among all age subgroups in elderly (>75 years old) 
patients [19]. Second, a review in 2016 including data of subgroups of patients over 75 years 
old in published RCTs, showed safety and efficacy of NOACs over warfarin, except for an 
increased risk of bleeding with dabigatran at the higher dose (150 mg versus 110 mg bid) 
[20]. Third, an analysis of US Medicare claims of patients >75 years old demonstrated that 
patients receiving apixaban experienced lower rates of stroke and bleeding than warfarin 
[21]. Fourth, an analysis of the oldest old (>90 years) patients with AF from Taiwan 
demonstrated NOACs as a favorable choice over warfarin for anticoagulation with net 
clinical benefit [22]. Therefore, current evidence supports NOACs as the best choice for 
elderly AF patients while avoiding the regimen of dabigatran 150 mg bid. 
 
Cost-effectiveness of NOACs versus VKAs 
As a relatively new group of drugs, the costs of NOACs were expected to be higher 
than conventional treatment with warfarin. Numerous studies have investigated if the higher 
direct costs of replacing VKAs with NOACs would be offset by reduced healthcare costs 
related to reduced stroke, bleeding, and their consequences. A 2016 systematic review [23] 
concluded that NOACS were cost-effective in several countries, independent of the health 
systems, direct costs of NOACs and VKAs, and costs of relevant diseases. These authors 
defined a drug as cost-effective when the incremental cost-effectiveness ratio was below the 
willingness-to-pay value,  ranging from: $US50,000 and $US100,000 in the United States; 
$CAD30,000 and $CAD50,000 in Canada; £20,000 and £30,000 in the UK; and €20,000 and 
€79,000 in the remaining European nations. The studies included were on average of high 
quality. Our study team updated the systematic review in the application to include NOACs 
in the WHO EML, including 64 cost-effectiveness analyses from 28 high- and middle-
income countries, but no analyses have yet been reported from low-income countries. Most 
studies used the same criteria to define cost-effectiveness, but newer cost-effectiveness 
analyses from the US have included costs from healthcare resource use and real-world data 
from health systems to determine the rate of stroke and bleeding rather than using data solely 
from RCTs, which have strengthened findings from earlier studies. All studies to date have 
demonstrated that NOACs are cost-effective in treating eligible patients with AF compared to 
VKAs [7].  
By the time of EML submission, NOACs were widely available in high-income 
countries and increasing elsewhere, with monthly costs ranging from 60 USD in India or 
Brazil to 300 USD in the US. In some countries, generic formulations of dabigatran are 
available [7].  
Antidotes for NOACs 
The introduction of idarucizumab, a monoclonal antibody against dabigatran that is 
widely available, and the more recently FDA-approved andexanet alfa, an antidote for 
apixaban and rivaroxaban, have responded to concerns about the need for an urgent reversal 
of NOACs, in the rejection of the previous (2014) application to include NOACs in WHO 
EML. Reversing NOACs with andexanet alfa seems to be associated with better outcomes in 
intracranial hemorrhages than reversing warfarin with plasma or 4-factor prothrombin 
complex concentrate [24,25]. 
 
Conclusions 
One of the 9 global targets to achieve a 25% reduction in the risk of premature 
mortality from non-communicable diseases by 2025 (the WHO 25X25 goals) focuses on 
increased coverage of essential medicines for non-communicable diseases, specifically - 80% 
availability of affordable basic technologies and essential medicines, including generics, 
required to treat major noncommunicable diseases in both public and private facilities [26].  
Successful inclusion of NOACs in the WHO EML is an important step forward in the global 
fight against cardiovascular morbidity and mortality, primarily through stroke prevention, 
especially in low- and middle-income countries, where the burden of disease is high and 
limited access to diagnosis and treatment translates into a higher burden of morbidity, 
mortality, and economic costs compared with higher-income countries hindering the 
achievement of the Sustainable Development Goals 3 and 10 [27].  
With the inclusion of NOACs in the WHO EML, the next step is to translate this 
evidence synthesis report and global application to national EML applications for better 
access and affordability of NOACs. The authors herein advocate national and regional 
healthcare authorities to implement strategies and policies to enhance availability and 
accessibility to NOACs for eligible AF patients. Moreover, the identification of obstacles to 
NOAC access and development of a rapid assessment tool for NOAC treatment in low-
income settings can further improve the accessibility to NOACs among those populations and 
people in greatest need. 
 
 
 
 
 
 Table 1. Brief summary of the characteristics of the 4 NOACs 
 NOAC Mechanism Pivotal Trial Year Type of 
drug 
Oral dosage 
form 
Low or 
adjusted 
dose 
Dabigatran IIa inhibitor RE-LY 2009 Capsule 150 mg bid 110 mg bid 
Rivaroxaban Xa inhibitor ROCKET 2011 Tablet 20 mg qd 15 mg qd 
Apixaban Xa inhibitor ARISTOTLE 2011 Tablet 5 mg bid 2.5 mg bid 
Edoxaban Xa inhibitor ENGAGE 2013 Tablet 60 mg qd 30 mg qd 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1. the efficacy of NOACs versus warfarin in preventing stroke and systemic 
embolism in patients with non-valvular AF based on data from RCTs and studies reporting 
real-world data 
Figure 2. The risks of major bleeding in non-valvular AF patients treated with NOACs 
versus warfarin based on data from RCTs and studies reporting real-world data 
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